NewKerala.com

Key Points

The Indian pharmaceutical market grew 7.9% in July, with cardiac and anti-diabetes therapies leading the surge. GLP-1 agonists like Semaglutide and Tirzepatide are gaining traction due to aggressive promotions. Biosimilars are emerging as a key growth driver, expanding at 15% annually. Experts highlight new product launches and price adjustments as major contributors to this upward trend.

Key Points: Indian Pharma Market Grows 7.9% with Cardiac and Diabetes Therapies Leading

  • Cardiac therapies surge 14.1% value growth in July
  • Anti-diabetes segment grows 9% with new product launches
  • GLP-1 agonists like Semaglutide and Tirzepatide drive market momentum
  • Biosimilars market expands at 15% CAGR, reaching Rs 3,900 crore
2 min read

Indian pharma market up by 7.9pc in July, cardiac & anti-diabetes therapies show strong volume

Indian pharma market expands 7.9% in July, driven by strong cardiac and anti-diabetes therapies, with GLP-1 agonists gaining momentum.

"New introductions and price growth have driven the market growth for the month of July for most of the therapies. – Sheetal Sapale, Pharmarack"

New Delhi, Aug 8

The Indian pharmaceutical market (IPM) grew 7.9 per cent in July this year, and the cardiac and anti-diabetes therapy segments have shown strong volume, according to a report.

The report by market research firm Pharmarack showed that cardiac and antidiabetes -- which together account for nearly 25 per cent of the overall domestic market -- recorded value growth of 14.1 per cent and 9 per cent, respectively.

Several super groups, such as urology and antineoplastics, each contributing around 2 per cent to the IPM’s monthly sales value, also reported double-digit value growth. The respiratory segment also registered a 9.2 per cent value growth.

“New introductions and price growth have driven the market growth for the month of July for most of the therapies,” said Sheetal Sapale, vice-president (commercial) at Pharmarack.

“Among the top therapies, only cardiac and anti-infectives have a strong volume growth. New introductions also drove the growth in the anti-diabetes segment,” Sapale added.

Meanwhile, the report highlighted that the GLP-1 agonists market continues to ride on a strong positive trend.

As per the report, Semaglutide and Tirzepatide continue to drive the growth of this market.

While Semaglutide is marketed as Rybelsus (oral), Wegovy (injections), Tirzepatide is sold under the brand Mounjaro. Both injectable medications are used to treat type 2 diabetes and promote weight loss.

“A strong upward momentum is seen for the month of July. This may be due to aggressive promotion of both the new launch brands in the market,” Sapale said.

Although the launch of Tirzepatide had impacted Semaglutide (Rybelsus), “we see Wegovy bringing back the molecule on a strong sales momentum,” Sapale said.

Further, the report also focused on strategic areas that drive exponential growth in the Indian pharma industry. This includes biologics and biosimilars, which are changing the canvas of the Indian pharma market.

“The biosimilars market is about Rs 3,900 Crore market today, growing at a five-year CAGR of 15 per cent,” Sapale said.

“With the changing landscape of disease patterns and associated complications, Biologics and Biosimilars play a critical role in the Indian pharma market,” Sapale added.

- IANS

Share this article:

Reader Comments

P
Priya S
As someone with diabetes, I'm happy to see innovation in anti-diabetes therapies. The new GLP-1 agonists sound promising, but I hope they don't burn a hole in our pockets like other imported medicines do.
A
Arjun K
Indian pharma industry is truly world class! We're not just making generics anymore but also innovating in biologics. Proud moment for Make in India initiative. 💊
S
Sarah B
While the growth numbers are impressive, I'm concerned about the aggressive marketing of these new drugs. Doctors should prescribe based on patient needs, not pharma promotions. Ethical practices matter!
K
Kavya N
The rise in cardiac and diabetes medicines shows our lifestyle diseases are increasing. Instead of just celebrating pharma growth, we need more awareness about prevention through better diet and exercise.
V
Vikram M
Biosimilars market growing at 15% CAGR is fantastic! This will help reduce treatment costs for serious diseases like cancer. Hope Indian companies can capture more global market share in this segment.
M
Michael C
Interesting data. I work in healthcare and can confirm the demand for these therapies is skyrocketing. India's ability to produce quality medicines at lower costs is benefiting patients worldwide.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50